Skip to main content

Media Category: Treatments

Real Life Experiences with Biosimilars

This expert-led webinar explored real-world experience with biosimilars in the treatment of Multiple Sclerosis (MS), with a particular focus on biosimilar natalizumab. Organized by ParadigMS, the session brought together Jelena Drulovic and Tjalf Ziemssen to discuss regulatory principles, clinical evidence, and practical challenges encountered in daily neurological practice. Professors reviewed the scientific and regulatory framework for biosimilars, emphasizing the concept of “totality of evidence” required for approval, including analytical, functional, pharmacokinetic, pharmacodynamic,...

Continue reading

Astrocytes and myelin – Clinical aspects: available and future treatment

This lecture explains how antibody-mediated pathology translates into clinical phenotypes and treatment strategies in Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Melinda Magyari contrasts the core targets, astrocytes (aquaporin-4) in NMOSD versus myelin/oligodendrocytes (MOG) in MOGAD, and shows how these mechanisms drive differences in relapse recovery, long-term disability, and therapeutic priorities. A major emphasis is placed on early antibody testing to avoid misdiagnosis (particularly as Multiple Sclerosis) and...

Continue reading

Sphingosine system – Clinical aspects: available and future treatment

This lecture reviews the clinical use of sphingosine-1-phosphate (S1P) receptor modulators in Multiple Sclerosis, with a focus on their mechanisms of action, receptor selectivity, pharmacokinetics, and safety considerations. Magd Zakaria discusses how differences in half-life, metabolism, and receptor targeting influence efficacy, adverse events, monitoring requirements, and treatment sequencing, including switching strategies and special populations such as women planning pregnancy. Key Insights from the Lecture: S1P receptor modulators exert their therapeutic effect by modulating...

Continue reading

Endocannabinoid system – pathology and pathway

The endocannabinoid system represents a complex and independent neurotransmitter system with a central role in maintaining homeostasis within the nervous and immune systems. In this lecture, Nikolaos Grigoriadis reviewed the biological foundations of the endocannabinoid system, its mechanisms of action in the central nervous system and immune response, and the growing experimental and clinical evidence supporting its neuroprotective and immunomodulatory functions, with particular relevance for Multiple Sclerosis and other neuroinflammatory conditions. Key Insights from the Lecture: The...

Continue reading

Endocannabinoid system – Clinical aspects: available and future treatment

In this keynote from Athens, medical cannabis is discussed as an emerging option for neuropathic pain and spasticity, with a particular focus on people living with multiple sclerosis. Evidence from clinical trials, large real-world cohorts and national prescribing data is reviewed, together with practical experience from a high-volume pain clinic. The presentation highlights how medical cannabis may reduce pain, spasticity and opioid use, while underlining current gaps in guidelines, regulatory hurdles and the need for careful titration and follow-up. Key Insights from the Lecture: Medical...

Continue reading

Immune reconstitution–pathology and pathway

In this keynote from Athens presented by Bart Van Wijmeersch, the concept of immune reconstitution therapy (IRT) in multiple sclerosis is examined from a mechanistic and clinical perspective. The presentation focuses on how targeted depletion and controlled repopulation of immune cells may rebalance dysregulated immunity, enhance tolerance, and reshape long-term disease activity. Key Insights from the Lecture: Immune reconstitution as a goal: restoring immune balance and tolerance is presented as a core objective in MS, by resetting dysregulated regulatory and effector cells. The...

Continue reading

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.